Volume 21 Number 3
31 March 2019

Home > Disciplines > Publications > Current Neuro-Oncology > Volume 21, Year 2019 > Number 3, 31 March

Stringfield O, Arrington JA, Johnston SK, Rognin NG, Peeri NC, Balagurunathan Y, Jackson PR, Clark-Swanson KR, Swanson KR, Egan KM, Gatenby RA, Raghunand N.
Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme.
Tomography. 2019 Mar 1, 2019;5(1):135-144
. doi: 10.18383/j.tom.2018.00052. PMID: 30854451. Observational study. ˍ

Xiao A, Brenneman B, Floyd D, Comeau L, Spurio K, Olmez I, Lee J, Nakano I, Godlewski J, Bronisz A, Kagaya N, Shin-Ya K, Purow B.
Statins affect human glioblastoma and other cancers through TGF-β inhibition.
Oncotarget. 2019 Mar 1, 2019;10(18):1716-1728
. doi: 10.18632/oncotarget.26733. PMID: 30899443. Laboratory investigation. ˍ

Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, Rutkowski S, Beilken A, Schmid I, Biassoni V, Gorelishev SK, Kramm C, Reinhard H, Schlegel PG, Kortmann RD, Reuter D, Bach F, Iznaga-Escobar NE, Bode U.
Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study.
J Neurooncol. 2019 Mar 4,
2019;143(1):107-113. doi: 10.1007/s11060-019-03140-z. PMID: 30830679. Interventional study. ˍ

Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, Geffrelot J, Kao W, Emery E, Berro DH, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Leconte A, Andre B, Léger A, Lelaidier A, Clarisse B, Stefan D.
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
BMC Cancer. 2019 Mar 4, 2019;19(1):198
. doi: 10.1186/s12885-019-5413-y. PMID: 30832617. Interventional study. ˍ

Minasi S, Baldi C, Pietsch T, Donofrio V, Pollo B, Antonelli M, Massimino M, Giangaspero F, Buttarelli FR.
Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
J Neurooncol. 2019 Mar 4,
2019;142(3):435-444. doi: 10.1007/s11060-019-03127-w. PMID: 30830680. Laboratory investigation. ˍ

Esquenazi Y, Moss N, Tabar V.
In Reply: Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.
Neurosurgery. 2019 Mar 5, 2019;84(5):E289-E290→. doi: 10.1093/neuros/nyz010→. PMID: 30834935→. Comment. ˍ
Refers to: Wang T et al., Letter: Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.
Neurosurgery. 2019 Feb 16,
2019;84(5):E288. doi: 10.1093/neuros/nyz009. PMID: 30770537. Comment. ˍ
In turn refers to: Esquenazi Y, et al., Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.
Neurosurgery. 2018 Jul 1, 2018;83(1):76-85. doi: 10.1093/neuros/nyx349. PMID: 28973417. Observational study. ˍ

Ito H, Nakashima H, Chiocca EA.
Molecular responses to immune checkpoint blockade in glioblastoma.
Nat Med. 2019 Mar 6, 2019;25(3):359-361. doi: 10.1038/s41591-019-0385-7. PMID: 30842671. Comment. ˍ
Refers to: Zhao J, et al., Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Nat Med. 2019 Feb 11, 2019;25(3):462-469. doi: 10.1038/s41591-019-0349-y. PMID:
30742119. Laboratory investigation. ˍ
- Schalper KA, et al., Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.
Nat Med. 2019 Feb 11, 2019;25(3):470-476. doi: 10.1038/s41591-018-0339-5. PMID: 30742120
. Interventional study. ˍ
- Cloughesy TF, et al., Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Nat Med. 2019 Feb 11, 2019;25(3):477-486. doi: 10.1038/s41591-018-0337-7. PMID: 30742122
. Interventional study. ˍ

Sridhar K, Srinivasan K.
Diffusion tensor imaging and tractography in diffuse intrinsic pontine glioma - A major determinant of resectability and description of a new subtype.
Neurol India. 2019 Mar 7, 2019;67(1):292-297
. doi: 10.4103/0028-3886.253625? PMID: 30860141. Case report. ˍ

Nobre L, Pauck D, Golbourn B, Maue M, Bouffet E, Remke M, Ramaswamy V.
Effective and safe tumor inhibition using vinblastine in medulloblastoma.
Pediatr Blood Cancer. 2019 Mar 8, 2019;66(6):e27694
. doi: 10.1002/pbc.27694. PMID: 30848061. Case report. ˍ


Santos VM, Marta GN, Mesquita MC, Lopez RVM, Cavalcante ER, Feher O.
The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma.
J Neurooncol. 2019 Mar 8,
2019;143(1):95-100. doi: 10.1007/s11060-019-03137-8. PMID: 30850928. Observational study. ˍ

Deweyert A, Iredale E, Xu H, Wong E, Schmid S, Hebb MO.
Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy.
J Neurooncol. 2019 Mar 9,
2019;143(1):49-56. doi: 10.1007/s11060-019-03145-8. PMID: 30852713. Laboratory investigation. ˍ

Akamandisa MP, Nie K, Nahta R, Hambardzumyan D, Castellino RC.
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Neuro Oncol. 2019 Mar 10, 2019;21(6):786-799. doi: 10.1093/neuonc/noz053. PMID: 30852603. Laboratory investigation. ˍ

Isikay I, Hanalioglu S, Basar I, Narin F, Bilginer B.
Survival Benefit with Gross Total Resection and Adjuvant Radiotherapy in Childhood Atypical Teratoid/Rhabdoid Tumors: Results of a Single-Center Cohort of 27 Cases.
Turk Neurosurg. 2019 Mar 11,
2019;29(5):689-697. doi: 10.5137/1019-5149.JTN.25406-18.1. PMID: 30875078. Observational study. ˍ


Krenzlin H, Behera P, Lorenz V, Passaro C, Zdioruk M, Nowicki MO, Grauwet K, Zhang H, Skubal M, Ito H, Zane R, Gutknecht M, Griessl MB, Ricklefs F, Ding L, Peled S, Rooj A, James CD, Cobbs CS, Cook CH, Chiocca EA, Lawler SE.
Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis.
J Clin Invest. 2019 Mar 11, 2019;130:1671-1683
. doi: 10.1172/JCI123375. PMID: 30855281. Laboratory investigation. ˍ


Hui CY, Rudra S, Ma S, Campian JL, Huang J.
Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients.
J Neurooncol. 2019 Mar 12,
2019;143(1):129-136. doi: 10.1007/s11060-019-03146-7. PMID: 30864102. Observational study. ˍ

Mueller S, Jain P, Liang WS, Kilburn L, Kline C, Gupta N, Panditharatna E, Magge SN, Zhang B, Zhu Y, Crawford JR, Banerjee A, Nazemi K, Packer RJ, Petritsch CK, Truffaux N, Roos A, Nasser S, Phillips JJ, Solomon D, Molinaro A, Waanders AJ, Byron SA, Berens ME, Kuhn J, Nazarian J, Prados M, Resnick AC.
A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
Int J Cancer. 2019 Mar 12,
2019;145(7):1889-1901. doi: 10.1002/ijc.32258. PMID: 30861105. Interventional study. ˍ

Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M.
Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
J Neurooncol. 2019 Mar 12,
2019;143(1):87-93. doi: 10.1007/s11060-019-03134-x. PMID: 30864101. Observational study. ˍ

Kieran MW, Goumnerova L, Manley P, Chi SN, Marcus KJ, Manzanera AG, Polanco MLS, Guzik BW, Aguilar-Cordova E, Diaz-Montero CM, DiPatri AJ, Tomita T, Lulla R, Greenspan L, Aguilar LK, Goldman S.
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.
Neuro Oncol. 2019 Mar 18, 2019;21(4):537-546
. doi: 10.1093/neuonc/noy202. PMID: 30883662. Interventional study. ˍ

Vargas López AJ, Sola Vendrell E, Fernández Carballal C.
Late recurrence of medulloblastoma after 17 years of complete remission.
J Clin Neurosci. 2019 Mar 21,
2019;64:33-35. doi: 10.1016/j.jocn.2019.03.028. PMID: 30905661. Case report. ˍ